From: Tumor-associated lymphangiogenesis predicts unfavorable prognosis of intrahepatic cholangiocarcinoma
Variable | Univariate analysis | |||
---|---|---|---|---|
Category | Median survival | p value | Confidence interval | |
Age | < 60 vs. ≥60 | 24.1 vs. 19.9 | 0.394 | 0.767–1.961 |
Gender | Male vs. Female | 19.3 vs. 26.1 | 0.074 | 0.957–2.554 |
HBV infection | Absent vs. Present | 20.2 vs. 25.1 | 0.118 | 0.411–1.106 |
Preoperative AFP (μg/l) | < 9 vs. ≥9 | 19.5 vs. 29.4 | 0.466 | 0.469–1.414 |
Preoperative CA19–9 (U/ml) | < 35 vs. ≥35 | 25.1 vs. 20.8 | 0.075 | 0.952–2.849 |
Tumor size (mm) | < 50 vs. ≥50 | 28.4 vs. 17.5 | 0.003* | 1.312–3.631 |
Vascular invasion | Absent vs. Present | 24.9 vs. 14.4 | 0.062 | 0.976–2.695 |
Lymph node metastasis | Absent vs. Present | 30.7 vs. 11.8 | < 0.001* | 1.916–5.215 |
Tumor number | Single vs. Multiple | 23.6 vs. 14.4 | 0.201 | 0.815–2.646 |
Histologic differentiation | Well/Moderate vs. Poor | 23.1 vs. 21.2 | 0.561 | 0.719–1.838 |
Perineural sheath infiltration | Absent vs. Present | 22.6 vs. 19.0 | 0.615 | 0.608–2.321 |
Distribution | Unilobar vs.Bilobar | 23.2 vs. 21.4 | 0.127 | 0.894–2.457 |
TNM stage | I/II vs. III/IV | 34.3 vs. 12.0 | < 0.001* | 2.189–6.403 |
MLVD | Low vs. High | 34.8 vs. 7.9 | < 0.001* | 3.963–12.620 |